These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15720419)

  • 21. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors predicting long-term survival in low-risk diffuse large B-cell lymphoma.
    Møller MB; Pedersen NT; Christensen BE
    Am J Hematol; 2003 Oct; 74(2):94-8. PubMed ID: 14508794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival.
    Ogawa S; Yamaguchi M; Oka K; Taniguchi M; Ito M; Nishii K; Nakase K; Ohno T; Kita K; Kobayashi T; Shiku H
    Br J Haematol; 2004 Apr; 125(2):180-6. PubMed ID: 15059140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma.
    Jang KY; Hwang SH; Kwon KS; Kim KR; Choi HN; Lee NR; Kwak JY; Park BH; Park HS; Chung MJ; Kang MJ; Lee DG; Kim HS; Shim H; Moon WS
    Am J Surg Pathol; 2008 Oct; 32(10):1523-31. PubMed ID: 18724249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
    Qi SN; Li YX; Wang H; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Zhou LQ; Yu ZH
    Cancer; 2009 Nov; 115(21):4980-9. PubMed ID: 19634158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.
    Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ
    Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Large-cell diffuse B-cell lymphoma: heterogenous origin and prognosis from the aspect of modern diagnosis].
    Soukup J; Krsková L; Mrhalová M; Kodet R; Campr V; Kubácková K; Trnĕný M
    Cas Lek Cesk; 2003; 142(7):417-22. PubMed ID: 14515445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry].
    Ye ZY; Cao YB; Lin TY; Lin HL
    Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):654-9. PubMed ID: 18194597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
    Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
    Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary lymphoma of bone: extranodal lymphoma with favourable survival independent of germinal centre, post-germinal centre or indeterminate phenotype.
    Heyning FH; Hogendoorn PC; Kramer MH; Holland CT; Dreef E; Jansen PM
    J Clin Pathol; 2009 Sep; 62(9):820-4. PubMed ID: 19734480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma.
    Uherova P; Ross CW; Schnitzer B; Singleton TP; Finn WG
    Am J Clin Pathol; 2001 Apr; 115(4):582-8. PubMed ID: 11293907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas.
    Bai M; Agnantis NJ; Skyrlas A; Tsanou E; Kamina S; Galani V; Kanavaros P
    Mod Pathol; 2003 May; 16(5):471-80. PubMed ID: 12748254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
    Obermann EC; Went P; Pehrs AC; Tzankov A; Wild PJ; Pileri S; Hofstaedter F; Dirnhofer S
    Oncol Rep; 2005 Dec; 14(6):1461-7. PubMed ID: 16273239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group.
    Shiozawa E; Takimoto M; Makino R; Adachi D; Saito B; Yamochi-Onizuka T; Yamochi T; Shimozuma J; Maeda T; Kohno Y; Kawakami K; Nakamaki T; Tomoyasu S; Shiokawa A; Ota H
    Leuk Res; 2006 Jul; 30(7):859-67. PubMed ID: 16406514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [International prognostic index in diffuse B large cell lymphosarcoma].
    Magomedova AU; Vorob'ev AI
    Ter Arkh; 2008; 80(3):71-6. PubMed ID: 18441690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma.
    Bilalovic N; Blystad AK; Golouh R; Nesland JM; Selak I; Trinh D; Torlakovic E
    Am J Clin Pathol; 2004 Jan; 121(1):34-42. PubMed ID: 14750238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
    Le Gouill S; Talmant P; Touzeau C; Moreau A; Garand R; Juge-Morineau N; Gaillard F; Gastinne T; Milpied N; Moreau P; Harousseau JL; Avet-Loiseau H
    Haematologica; 2007 Oct; 92(10):1335-42. PubMed ID: 18024371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
    Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
    Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors.
    Adams H; Tzankov A; d'Hondt S; Jundt G; Dirnhofer S; Went P
    Hum Pathol; 2008 Sep; 39(9):1323-30. PubMed ID: 18614198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.